Meet the dirt cheap ASX 200 stock that could rocket 75%

Bell Potter thinks investors should be snapping up this stock while it is down in the dumps.

| More on:
A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Neuren Pharmaceuticals Ltd (ASX: NEU) shares were out of form on Tuesday after getting caught up in the market selloff.

The ASX 200 stock ended the day 6% lower at $11.40.

This leaves the pharmaceutical company's shares trading within sight of their 52-week low of $10.90.

One leading broker thinks that investors should be seizing this opportunity to buy a quality company at deep discount to its true value.

What is the broker saying about this ASX 200 stock?

According to a note out of Bell Potter, its analysts have been pleased with the performance of the company's Daybue product, which it receives royalties from. It said:

Daybue CY24 US sales of US$348m was within guidance and slightly above consensus. Acadia's CY25 guidance for US sales is US$380-405m (9-16% growth). Our US$385m forecast is comfortably within this range and remains unchanged following the update. The US-only guidance implies CY25 royalties to NEU of US$41-44m, so not a major difference to NEU at either end of this range.

Most pleasingly, even the low end of CY25 guidance reflects HSD growth yoy, providing confidence in Daybue's continued growth outlook in the US excluding any Canadian or EU contributions. Note management expects Daybue 1Q25 US sales to have a similar QoQ seasonality decline as seen in 1Q24 before rebounding later in the year.

In light of this, the broker has reaffirmed its buy rating with a trimmed price target of $20.00.

Based on where the ASX 200 stock is currently trading, this implies potential upside of 75% for investors over the next 12 months.

Second asset for free

Bell Potter highlights at the current share price, the market is ascribing no value to Neuren's second asset. It explains:

Regarding catalyst timing, it will be ~2 years until the next major clinical catalyst, being the first Ph3 readout for NNZ-2591, which offers clear re-rating potential but remains some time away.

NEU has unrivalled balance sheet strength to prosecute future NNZ-2591 development yet effectively zero value is currently attributed to this asset, likely due to the Ph3 readout timing. We maintain our BUY recommendation which continues to be driven by a positive outlook on NNZ-2591. Licensing income from Daybue alone supports the current share price.

All in all, this could be an ASX 200 stock to buy. Especially if you're looking for exposure to this side of the market (and big potential returns!).

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Man looks shocked as he works on laptop on top a skyscraper with stockmarket figures in graphic behind him.
Healthcare Shares

Macquarie tips more than 100% upside for this ASX All Ords healthcare stock

This company could be set to soar.

Read more »

A little boy, soon to be a brother, kisses and holds his mum's pregnant tummy.
Healthcare Shares

Monash IVF shares fall 25% following second embryo incident

Its been a forgettable start to 2025 for Monash IVF shareholders.

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Buying CSL shares? Meet your new board director

CSL’s new board director has spent the last 11 years in an executive role at Australia’s $240 billion Future Fund.

Read more »

A man sits in contemplation on his sofa looking at his phone as though he has just heard some serious or interesting news.
Technology Shares

Up 60% in two months, is it too late to buy Pro Medicus shares?

Pro Medicus has been delivering solid returns for years. Can the trend continue?

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why this ASX All Ords stock is jumping 9% today

What has put a rocket under this stock on Friday? Let's find out.

Read more »

A hipster dude leaps in the air with glee, seeing positive news on his tablet.
Healthcare Shares

Which ASX 200 stock is jumping 11% on big news?

Investors are responding very positively to a big announcement.

Read more »

Senior woman using cpap machine to stop choking and snoring from obstructive sleep apnoea with bokeh and morning light background.
Healthcare Shares

Up more than 75% since October 2023 — are ResMed shares a buy, hold or sell?

ResMed shares have surged more than 75% since October 2023, but is it too late to buy? We break down…

Read more »

Stethoscope with a piggy bank in the middle.
Broker Notes

Australian health insurance: Does Macquarie prefer Medibank or NIB shares?

Medibank and NIB shares have both surged in 2025. Here’s what Macquarie expects now.

Read more »